AnaptysBio Sells Royalty Interest In Cancer Drug For $45M
AnaptysBio Inc (NASDAQ:ANAB), a clinical-stage biotechnology company focused on immunology therapeutics, has sold its royalty interest on future global…
Europe Approves Novavax’s COVID-19 Vaccine Booster For Adults
The European Commission has approved the expanded conditional approval of Novavax Inc’s (NASDAQ:NVAX) Nuvaxovid COVID-19 vaccine as a homologous and heterologous booster…
Regulus Shares Surge After Early-Stage RGLS8429 Data In Rare Kidney Disease
Biopharmaceutical company Regulus Therapeutics Inc (NASDAQ: RGLS) shares jumped after topline safety and Pharmacokinetic (PK) data from its Phase 1 single-ascending dose (SAD) trial of RGLS8429 in autosomal dominant polycystic kidney disease (ADPKD).
Novartis’ Cosentyx Shows To Ease Symptoms In Painful Skin Condition
Novartis AG (NYSE:NVS) announced the results from two Phase 3 studies (SUNSHINE and SUNRISE) of Cosentyx (secukinumab) in moderate-to-severe hidradenitis suppurativa…
Cardiff Oncology Shares Pop After Lead Asset In KRAS-Mutated Colorectal Cancer
Clinical-stage biotech Cardiff Oncology Inc (NASDAQ:CRDF) announced new preclinical and clinical data from its lead program in KRAS-mutated metastatic colorectal carcinoma (mCRC)…
U.S. FDA Accepts Acadia’s Filing For Rett Syndrome Candidate Under Priority Review
The U.S. Food and Drug Administration (FDA) has accepted for filing Acadia Pharmaceuticals’ (NASDAQ: ACAD) New Drug Application (NDA) of trofinetide for the treatment of Rett syndrome.
The regulatory agency has granted a priority review and assigned a PDUFA action date of March 12, 2023.
BeiGene’s Tislelizumab Shows Non-Inferiority In Overall Survival, Safety Vs Standard Treatment In Solid Tumors
BeiGene Limited (NASDAQ:BGNE) shared updates from its solid tumor development program for tislelizumab at the European Society for Medical Oncology (ESMO)…
Ra Medical Systems Announces Reverse Merger; Combined Company To Focus On Cardiac Arrhythmias
Ra Medical Systems Inc (NYSE:RMED) has agreed to merge with privately held Catheter Precision Inc, a medical device and technology company focused…
Mersana Shares Climb As FDA Grants Fast Track Status To Triple-Negative Breast Cancer Candidate
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Mersana Therapeutics’ (NASDAQ: MRSN) lead candidate XMT-1660 for the treatment of adult patients with advanced or metastatic triple-negative breast cancer (TNBC).
Johnson & Johnson Reaches $300M Settlement In Australian Pelvic Mesh Lawsuit
Johnson & Johnson (NYSE:JNJ) has reached a A$300 million settlement in two Australian class action suits filed by Shine Lawyers for…